Mechanical circulatory support and the associated cardiopulmonary therapies are a perfect example of how engineering, physiology, and clinical practice are interconnected. There is rarely a single breakthrough that leads to progress in this field. Instead, it is a series of small changes in device design, materials, and protocols that hospitals gradually adopt after publication and patenting. Eventually, the public record of these endeavors becomes a guide in itself, comprising journal articles that document the challenges and solutions, patent claims that define the design direction, and book chapters that distill the experience into a developer’s guide.
In this context, Kurt A. Dasse, Ph.D., has amassed a significant body of work, reflected not only in peer-reviewed publications but also in patent activities and writing related to device development and commercialization. Dasse, who was born in Valparaiso, Indiana, on July 7, 1949, was trained in physiology. He later combined his academic and industry experience and focused on developing cardiac and respiratory technologies. Accounts of his professional life, based on publicly available information, also narrate his tenure in leadership roles of mechanical circulatory support programs and nitric oxide delivery systems for cardiopulmonary care.
Short public biographical notices often credit Dasse with more than one hundred peer-reviewed journal articles. Such a volume of publications suggests that he has been continuously involved in research and development for several decades rather than for a brief period. Though thorough bibliographic confirmation requires a complete index-based review, the set of journals most frequently linked to his work is in the field of device support and related clinical disciplines. Among them are journals focusing on artificial organs and mechanical circulatory support, e.g., ASAIO Journal and Artificial Organs, as well as clinically oriented publications that address device efficacy, complications, and patient selection.
The subject areas associated with this publication record tend to cluster around several recurring problems in device support. One cluster focuses on hemodynamics and blood handling, topics that determine whether a pump supports circulation while minimizing the risk of hemolysis and thrombosis. Another cluster centers on clinical and regulatory questions: trial design, device indications, post-implant management, and how data are presented to regulators and clinicians. A third cluster sits in the practical space between engineering and bedside care, where design constraints, surgical workflows, and maintenance requirements shape outcomes. In the mechanical circulatory support literature, these themes often recur because they reflect real constraints that persist even after a new pump generation is released.
The broader arc matters because publication volume alone does not explain how work travels. In this field, peer-reviewed articles can serve as technical documentation, clinical evidence, and a means to standardize methods across multiple centers. That role becomes clearer when the publication record is read alongside patent filings and later writing on development pathways.
Patent activity provides another view into the same work, because it organizes ideas into claims about geometry, flow, and delivery mechanisms. Summaries of Dasse’s portfolio describe issued and pending patents related to blood pump design, flow-path optimization, and inhaled nitric oxide delivery systems. In device support, “blood pump geometry” is not a vague phrase. It typically refers to impeller profiles, housing shapes, bearing or levitation arrangements, and the flow paths that influence shear exposure. “Flow optimization” often means design choices that aim to reduce stagnant zones, manage heat, and keep the system stable across operating ranges.
The nitric oxide platform patents point to a different category of claims: device-drug combination systems that deliver gaseous therapy while meeting practical constraints in hospital and portable settings. Public reporting on GeNO’s leadership changes in 2012 and 2013 describes the company’s focus on nitric oxide generation and delivery platforms and identifies Dasse as president and later chief executive officer during that period. While those announcements do not list specific patent claims line by line, they clarify the program’s focus and the regulatory context typical of combination products, in which device controls and drug-delivery oversight fall under overlapping frameworks.
Claims only matter insofar as they map to clinical benefit, and the mapping is rarely direct. A pump design change can reduce hemolysis in bench testing yet create new operational constraints in the clinic. A delivery system can increase portability, but it raises questions about monitoring and safety protocols. The clinical contribution, therefore, tends to appear in paired forms: a patent that stakes out a design approach, and subsequent evidence in publications, trials, or post-market reports that clarify performance boundaries.
In recent years, Dasse has also been linked to book chapters on combination products and route-to-market topics. The titles of the materials you provided, including “Combination Products: Regulatory and Development Strategies” and “Route to Market for Emerging Biomedical Technologies,” place greater emphasis on development systems rather than on a single device. That shift reflects a common pattern in long tenure device careers. After multiple product cycles, contributors often publish practical frameworks that a mixed audience can use: engineers, regulatory leads, clinicians involved in trials, and executives responsible for financing and commercialization.
The intended audience for this type of writing typically includes classroom and professional training settings, where case-based learning helps translate a long sequence of decisions into principles applicable to new programs. Topics such as FDA pathway planning for hybrid device-drug products, design control documentation, and clinical evidence strategy can be taught in an abstract manner. However, the material tends to carry more weight when tied to real development programs. Public sources also place Dasse in the context of an MIT Engineering Leadership Program in 2011, where the course content emphasized lessons from engineering leadership, a setting consistent with the route-to-market framing described in his later written contributions.
Separate from technical writing, Dasse’s public author profile includes fiction titles such as Law and the Heart and The Sleep Doctors, with other work described in online summaries. These books sit outside the patent and device literature. However, their presence in his bibliography matters for how his public record is organized, as it creates two tracks of authorship: technical work directed at clinical and device audiences, and narrative work directed at general readers.
Influence on medical devices rarely shows up in one metric. Clinical guideline citations, competitor patent references, and acquisition history all provide partial signals. In Dasse’s case, the acquisition record of the programs he led provides an externally documented marker of market interest in specific product families. In 2011, Thoratec announced the acquisition of Levitronix’s medical business in a deal reported to be worth up to $150 million, including systems such as CentriMag and PediMag. This type of transaction does not validate every technical claim, but it does indicate that established firms saw value in the technology, its installed base, and its future development options.
Patent families can also be referenced indirectly through competitor filings and due diligence in acquisitions, especially when pump design approaches converge. References do not always indicate agreement or direct dependence, but they show that a claim set has entered the competitive landscape. In parallel, clinical citations tend to reflect a different kind of influence. A device data citation in a guideline or consensus statement signals that the results were considered relevant to practice, whether for patient selection, adverse-event management, or procedural protocols. Those citations, when present, place the work into an evidence chain that guides decisions beyond a single institution.
Dasse’s public recognition record includes a 2025 announcement naming him the recipient of ASAIO’s Pushpa and Kewal Gupta Lifetime Achievement Award, which recognized contributions to therapies for cardiovascular and pulmonary diseases and was presented at the ASAIO annual meeting in New Orleans. Awards are not alternatives to independent evaluation of technical output, but they do show how professional societies sometimes summarize long-term participation in a field.
Taken together, the publication arc, patent claims, and later route-to-market writing create a composite record: research and development communicated through journals, technical positions stated through patent language, and development lessons organized for training and reference. That record, rather than any single product or role, is what remains visible when the work is viewed through public documentation.
